Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer
Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer
- Move reflects increasing investment in AI as driving force for innovation and productivity.
- Company will host Innovation Summit in December focused on AI in R&D.
- 此舉反映了對人工智能投資日益增長，人工智能是創新和生產力的驅動力。
- 公司將於12月舉辦創新峯會，重點關注研發領域的人工智能。
WASHINGTON, June 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role.
華盛頓，2024年6月5日 / -- 丹納赫公司（紐交所股票代碼：DHR）是一家全球科學和技術創新者，今天宣佈成立首席數據和人工智能（AI）官職位，並任命 Martin Stumpe 博士擔任該職位。PRNewswire丹納赫公司越來越注重人工智能的非有機投資，加強內部能力，並與領先的學術機構合作。該公司將於12月舉辦第三屆丹納赫峯會，匯聚有遠見的領袖和創新者，探討人工智能對生物製藥研發的潛在影響。
Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danaher, said: "We are delighted to welcome Dr. Stumpe to our team. His extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting Danaher's AI and data strategy to advance innovation."
丹納赫公司高級副總裁兼首席科學官Jose-Carlos Gutierrez-Ramos表示：“我們很高興歡迎 Stumpe 博士加入我們的團隊。他在利用人工智能推動科學和操作進展方面的豐富經驗對於進一步支持丹納赫的人工智能和數據策略以推動創新是至關重要的。”Stumpe 博士最近擔任Tempus的人工智能主管，領導以人工智能技術爲目標的精準醫療倡議。在Tempus之前，他在Google創立了癌症病理學項目，旨在利用人工智能技術提高癌症檢測和分級的準確性，並且曾經是NASA Ames研究中心的Kepler團隊的成員。Stumpe博士擁有德國馬普生物物理化學研究所的計算和理論物理學博士學位。他向 Gutierrez-Ramos 博士彙報。
Dr. Stumpe most recently served as Chief of AI at Tempus, where he spearheaded AI initiatives aiming to make precision medicine a reality. Prior to Tempus, he founded the Cancer Pathology project at Google – which aimed to enhance the accuracy of cancer detection and grading using AI techniques – and was part of the Kepler team at NASA's Ames Research Center. Dr. Stumpe holds a Ph.D. in Computational & Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Germany. He will report to Dr. Gutierrez-Ramos.
Danaher是一家領先的全球生命科學和診斷技術創新公司，致力於加速科學和技術的力量以改善人類健康。我們的業務與客戶緊密合作，解決困擾全球患者的許多重要健康挑戰。丹納赫的先進科學和技術 - 以及經過驗證的創新能力 - 幫助加快診斷速度，提高準確性，並幫助降低可持續發現，開發和提供改變生命的治療所需的時間和成本。我們擁有約63,000名全球員工，致力於科學卓越，創新和持續改進，幫助確保丹納赫正在改善今天數十億人的生活質量，併爲健康，更可持續的明天打下基礎。了解更多信息：
Danaher is increasingly focusing on AI through inorganic investment, strengthening internal capabilities, and collaborating with leading academic institutions. In December, the company will host the third annual Danaher Summit, bringing together visionary leaders and innovators to discuss AI's potential impact on biopharmaceutical research and development.
本文中沒提到的歷史事實，包括丹納赫公司的人工智能和數據策略、人工智能的焦點領域以及丹納赫認爲或預計將來會發生的任何其他事件或發展，都是“前瞻性”聲明。根據聯邦證券法，有許多重要因素可能導致實際結果、發展和業務決策與此類前瞻性聲明所示的建議或指示有所不同，您不應過度依賴任何此類前瞻性聲明。這些因素包括，但不限於，丹納赫的 SEC 文件中列出的因素，包括我們2023年年度報告的10-K表和2024年第一季度的10-Q表。這些前瞻性聲明僅適用於本發佈日期，丹納赫除依法要求外，不承擔更新或修訂任何前瞻性聲明的任何義務，無論是因爲獲得新信息，還是因爲未來事件和發展或其他的原因。
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
關於丹納赫
丹納赫是一家領先的全球生命科學和診斷技術創新公司，致力於加速科學和技術的力量以改善人類健康。我們的業務與客戶緊密合作，解決困擾全球患者的許多重要健康挑戰。丹納赫的先進科學和技術 - 以及經過驗證的創新能力 - 幫助加快診斷速度，提高準確性，並幫助降低可持續發現，開發和提供改變生命的治療所需的時間和成本。專注於科學卓越，創新和持續改進，我們全球約有63,000名員工，幫助確保丹納赫正在改善今天數十億人的生活質量，併爲健康，更可持續的明天打下基礎。了解更多信息：www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including any statements regarding Danaher's AI and data strategy, AI focus areas and any other events or developments that Danaher believes or anticipates will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the factors set forth in Danaher's SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2024. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, Danaher does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
前瞻性聲明
本發佈中的聲明，除了有關丹納赫公司的人工智能和數據策略、人工智能的焦點領域以及丹納赫認爲或預計將來會發生的任何其他事件或發展的聲明外，如果任何聲明是“前瞻性”的，在聯邦證券法的意義上，都是屬於這種前瞻性聲明的。這裏有許多重要因素可能導致實際結果、發展和業務決策與所示建議或指示有所不同，您不應過度依賴任何此類前瞻性聲明。這些因素包括，但不限於，丹納赫的 SEC 文件中列出的因素，包括我們2023年年度報告的10-K表和2024年第一季度的10-Q表。這些前瞻性聲明只適用於本發佈日期，丹納赫除依法要求外，不承擔更新或修訂任何前瞻性聲明的任何義務，無論是因爲獲得新信息，還是因爲未來事件和發展或其他的原因。
SOURCE Danaher Corporation
DANAHER 資料來源
譯文內容由第三人軟體翻譯。